Actively Recruiting
JS207 Combination Therapy in Triple-negative Breast Cancer
Led by Shanghai Junshi Bioscience Co., Ltd. · Updated on 2026-04-15
80
Participants Needed
22
Research Sites
183 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.
CONDITIONS
Official Title
JS207 Combination Therapy in Triple-negative Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 to 75 years
- Voluntary participation in the clinical study
- Histologically confirmed unresectable, locally advanced, or metastatic triple-negative breast cancer (no HER2, ER, or PR expression)
- No prior systemic antitumor therapy for locally advanced or metastatic TNBC
- Prior neoadjuvant or adjuvant systemic anti-tumor therapy allowed if recurrence/metastasis occurred at least 6 months after therapy; if taxane was used, disease-free interval must be at least 12 months
- Adequate organ function
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 12 weeks
- Measurable disease as defined by RECIST v1.1
You will not qualify if you...
- Untreated or active central nervous system (CNS) metastases
- Uncontrolled pleural effusion, pericardial effusion, or ascites
- Tumor encasement of important vessels or significant necrosis and cavitation posing hemorrhage risk
- History of significant bleeding tendency or severe coagulation disorder
- Uncontrolled hypertension
- Active autoimmune diseases requiring systemic treatment within 2 years prior to first dose
- History of interstitial lung disease, previous noninfectious pneumonitis treated with corticosteroids, or active pneumonia seen on screening radiology
- Severe eye disorders or symptoms such as xerophthalmia or keratoconjunctivitis sicca
- Severe cardiovascular disease
- Serious infection (CTCAE grade greater than 2) within 28 days prior to first dose
- Previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or agents targeting other T cell receptors in (neo)adjuvant therapy unless disease-free interval is at least 6 months
- Prior treatment with antibody-drug conjugates linked to MMAE or targeting Nectin-4, such as Enfortumab Vedotin, is not allowed
- History of another malignancy within 5 years prior to first dose
- Any condition making participant unsuitable for study treatment as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 22 locations
1
Anhui Provincial Cancer Hospital
Hefei, Anhui, China, 230000
Not Yet Recruiting
2
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
3
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China, 100071
Actively Recruiting
4
Guangdong women and children's hospital and health institute
Guangzhou, Guangdong, China, 511400
Not Yet Recruiting
5
Affiliated Hospital of Hebei University
Baoding, Hebei, China, 071030
Actively Recruiting
6
Harbin Medical University Affiliated Cancer Hospital
Harbin, Heilongjiang, China, 150001
Not Yet Recruiting
7
Harbin Medical University Affiliated Cancer Hospital
Harbin, Heilongjiang, China, 150001
Not Yet Recruiting
8
Henan Cancer Hospital
Zhangzhou, Henan, China, 450003
Actively Recruiting
9
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Actively Recruiting
10
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China, 210009
Actively Recruiting
11
Jiangsu Province Hospital
Nanjing, Jiangsu, China, 210029
Not Yet Recruiting
12
Nanchang People'S Hospital
Nanchang, Jiangxi, China, 330000
Not Yet Recruiting
13
Jilin University First Hospital
Changchun, Jilin, China, 130021
Actively Recruiting
14
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China, 116027
Actively Recruiting
15
The First Hospital of China Medical University
Shenyang, Liaoning, China, 110002
Actively Recruiting
16
Liaoning Cancer Hospital&Institute
Shenyang, Liaoning, China, 110801
Actively Recruiting
17
Ceneral Hosipital of Ningxia Medical University
Yinchuan, Ningxia, China, 750000
Not Yet Recruiting
18
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China, 266035
Actively Recruiting
19
The First Affiliated Hospital of Xi'an Jiaotong University
Xian, Shanxi, China, 710061
Actively Recruiting
20
Xi'an International Medical Center Hospital
Xian, Shanxi, China, 710100
Actively Recruiting
21
Affiliated Tumor Hospital of Xinjiang Medical University
Ürümqi, Xinjiang Uygur Autonomous Region, China, 830000
Actively Recruiting
22
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310000
Not Yet Recruiting
Research Team
C
Chaoqiang Yang, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here